Integrated flow cytometry and sequencing to reconstruct evolutionary patterns from dysplasia to acute myeloid leukemia

Autor: Catia Simoes, Maria-Carmen Chillon, David Martínez-Cuadrón, Maria-José Calasanz, María-Belén Vridiales, Iria Vazquez, Montserrat Hernández-Ruano, Beñat Ariceta, Paula Aguirre-Ruiz, Leire Burgos, Diego Alignani, Sarai Sarvide, Sara Villar, Ana Alfonso Pierola, Felipe Prosper, Rosa Ayala, Joaquin Martínez-López, Juan Miguel Bergua Burgues, Susana Vives, Jose A. Perez-Simon, Maria Garcia-Fortes, Teresa Bernal del Castillo, Mercedes Colorado, Mayte Olave, Juan I. Rodríguez-Gutiérrez, Jorge Labrador, Marcos González, Jesús F. San-Miguel, Miguel Ángel Sanz, Pau Montesinos, Bruno Paiva

Publikováno v: Blood Advances
r-IIS La Fe. Repositorio Institucional de Producción Científica del Instituto de Investigación Sanitaria La Fe
instname
Blood advances, 2023, 7(1), 167-173

Clonal evolution in acute myeloid leukemia (AML) originates long before diagnosis and is a dynamic process that may affect survival. However, it remains uninvestigated during routine diagnostic workup. We hypothesized that the mutational status of bo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e0ebb29de33b779945272eff40de879e
https://fundanet.iislafe.san.gva.es/publicaciones/ProdCientif/PublicacionFrw.aspx?id=17131

Poster: AML-122 Midostaurin Maintenance versus Allo SCT versus W&W in FLT3-Mutated AML: A 'Real-Life' Multicenter Study

Autor: Adolfo de la Fuente, Marina Diaz Beya, Paola Beneit, Ainhoa Fernandez Moreno, Montserrat Arnan Sangerman, Ana Garrido, Susana Vives Polo, Maria Garcia Fortes, Antonia Sampol Mayol, Jorge Labrador, Antoni Garcia Guinon, Cristina Gil Cortes, Juan Bergua, Mayte Olave, Maria Luz Amigo, Xavi Ortin, Ferran V Poster, Monica Estevez, Antonio Diaz-Lopez, Josefina Serrano, Mar Tormo

Publikováno v: Clinical Lymphoma Myeloma and Leukemia. 22:S129

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::a7d629dbac86e0266a051c77736ffdff
https://doi.org/10.1016/s2152-2650(22)00768-6

Clinical outcomes after CPX‐351 in patients with high‐risk acute myeloid leukemia: A comparison with a matched cohort from the Spanish PETHEMA registry

Autor: Teresa Bernal, Ainhoa Fernández Moreno, Almudena de LaIglesia, Celina Benavente, Ana García‐Noblejas, Daniel García Belmonte, Rosalía Riaza, Olga Salamero, Maria Angeles Foncillas, Alicia Roldán, Víctor Noriega Concepción, Laura Llorente González, Juan Miguel Bergua Burgués, Soraya Lorente de Uña, Gabriela Rodríguez‐Macías, Adolfo de la Fuente Burguera, Maria José García Pérez, Jose Luis López‐Lorenzo, Pilar Martínez, Concepción Aláez, Marta Callejas, Carmen Martínez‐Chamorro, José Rifón Roca, Lourdes Amador Barciela, Armando V. Mena Durán, Karoll Gómez Correcha, Esperanza Lavilla Rubira, María Luz Amigo, Ferran Vall‐llovera, Ana Garrido, María García‐Fortes, Dunia de Miguel Llorente, Anastasia Aules Leonardo, Carlos Cervero, Rosa Coll Jordá, Manuel M. Pérez‐Encinas, Marta Polo Zarzuela, Angela Figuera, Guillermo Rad, David Martínez‐Cuadrón, Pau Montesinos

Publikováno v: Cancer Medicine, Vol 12, Iss 14, Pp 14892-14901 (2023)

Abstract Background CPX‐351 is approved for the treatment of therapy related acute myeloid leukemia (t‐AML) and AML with myelodysplastic related changes (MRC‐AML). The benefits of this treatment over standard chemotherapy has not been addressed

Externí odkaz: https://doaj.org/article/9c1db4405e274742a000602740ddeff0

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.